I am a board-certified medical oncologist whose clinical practice is devoted to the care of patients with breast cancer, and I work as part of a multidisciplinary team to treat women with this disease. My research activities are focused on developing new therapeutic approaches for the treatment of breast cancer, and investigating the impact of these therapies on fertility and sexual health.
Read more Read less
Currently, I am involved in clinical trials to evaluate anti-angiogenic agents, which are designed to cut off the tumor’s blood supply. In addition, I am investigating therapies that interfere with estrogen in women with hormone-receptor-positive breast cancer, and therapies that are targeted to other growth factor signaling pathways (e.g. the HER2 pathway). My colleagues and I are investigating these approaches when they are given alone or in combination (for example, giving both anti-estrogen therapy and anti-angiogenic therapy). I am also involved in clinical trials evaluating the effects of breast cancer therapy (e.g. chemotherapy) on ovarian reserve in premenopausal women, and the use of low dose intravaginal estrogen to ameliorate symptoms of vaginal dryness in postmenopausal women.
I am a member of a number of medical groups including the New York Metropolitan Breast Cancer Group, the American Society of Clinical Oncology (ASCO), and the American College of Physicians/American Society of Internal Medicine. I also serve on the National Cancer Institute-sponsored Cancer and Leukemia Group B (CALGB) Breast Committee, the ASCO Breast Cancer Education Committee, and the Endocrine-Related Cancer Journal Editorial Board.
I am an ad hoc reviewer for several clinical journals including The Lancet, the New England Journal of Medicine, Journal of Clinical Oncology, Clinical Cancer Research, and Breast Cancer Research and Treatment. I have written more than 20 peer-reviewed articles, review articles, and book chapters.
I work closely with nurse practitioner Nora Messinger. We combine our expertise to provide comprehensive care to our patients at every step of their cancer journey.
- Clinical Expertise: Breast Cancer
- Awards and Honors: Castle Connolly: New York Magazine Top Doctors (2005-2006; 2015-2017)
- Languages Spoken: English
- Education: MD, University of Chicago
- Residencies: Internal Medicine - University of Chicago Hospitals
- Fellowships: Hematology/Medical Oncology - Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology
Dickler M and Hudis CA. Aromatase Inhibitors for Treatment of Breast Cancer: From Metastatic Disease to Prevention. In: Principles and Practice of Oncology, Updates, 2003, 17:1-14.
Dickler MN, Contributing author, “Fulvestrant (Faslodex) for Advanced Breast Cancer,” Med Lett Drugs Ther 2002; 44:65-66.
Read more Read less
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Read more Read less
Clinical Trials Led by Maura N. Dickler
- A Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
- A Phase I Study of GDC-9545 Alone or with Palbociclib and/or Hormonal Therapy to Treat Advanced or Metastatic ER-Positive, HER2-Negative Breast Cancer
- A Phase IB Study of Abemaciclib plus Hormonal Therapy in Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
- A Phase II Study of Abemaciclib plus Trastuzumab versus Trastuzumab with Standard Chemotherapy in Patients with Advanced Breast Cancer
- Two Studies of GDC-0032: A Phase I Study of GDC-0032 for Solid Tumors with Increased PI3K Activity, and a Phase II Study of GDC-0032 with Fulvestrant in Patients with Advanced Breast Cancer
Clinical Trials Co-Investigated by Maura N. Dickler
- A Long-Term Study of Sexual and Reproductive Health in Women with Breast Cancer and Lymphoma
- A Phase I Study of GDC-0077 with Palbociclib and/or Letrozole in Patients with Breast Cancer
- A Phase I Study of LJM716, BYL719, and Trastuzumab in Women with Metastatic HER2-Positive Breast Cancer
- A Phase I Study of SGN-LIV1A in Women with Metastatic Breast Cancer
- A Phase I/IB Study of LSZ102 Alone and with LEE011 or BYL719 in Patients with Metastatic Estrogen Receptor-Positive Breast Cancer
- A Phase IB Study of Debio 1347 plus Fulvestrant in Women with Metastatic Breast Cancer
- A Phase II Study of Alpelisib plus Fulvestrant or Letrozole for Patients with Metastatic Breast Cancer (the BYLIEVE Study)
- A Phase III Study of Standard Hormonal Therapy Alone and with Palbociclib in Patients with Early-Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer
- A Phase III Study of Taselisib plus Fulvestrant versus Placebo plus Fulvestrant in Women with Recurrent or Metastatic HR-Positive HER2-Negative Breast Cancer
- A Study Assessing Fluorestradiol PET/CT for Imaging Estrogen Receptor Status
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more